PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study

The University of Alabama at Birmingham

Status and phase

Completed

Phase 1

Conditions

Metastatic Prostate Cancer

Treatments

Drug: [68Ga]PSMA-PET/MRI or PET/CT

Study type

Interventional

Funder types

Other

Identifiers

NCT04086966

R18-190 IRB-300003826

Details and patient eligibility

About

This pilot study will investigate the use of PSMA-PET/MRI (Positron Emission Tomography/ Magnetic Resonance Imaging)to guide radiation treatment planning in patients with known or suspected locally metastatic prostate cancer at the time of diagnosis. Patients will undergo a single PSMA-PET/MRI (or PET/CT (Computed Tomography) in some circumstances) prior to initiation of treatment. Following development of a PSMA-PET guided radiation treatment plan, therapeutic radiation will be delivered per standard-of-care parameters and assessments of feasibility and tolerability will be performed.

Enrollment

10 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Biopsy-proven treatment-naïve prostate adenocarcinoma with pelvic metastases known to suspected on standard-of-care staging imaging
Eligibility and plan to undergo definitive radiation therapy for prostate cancer per established standard-of-care radiation oncology clinical guidelines
Be at least 18 years of age

Exclusion criteria

Inability to tolerate or undergo PET/MRI or PET/CT
Previous or current hematologic or lymphatic disorder (including leukemia, lymphoma, Castleman's disease, etc.)
Recurrent prostate adenocarcinoma
Known distant metastatic disease
Current or prior treatment for prostate cancer
Known allergy to glucagon
Previous diagnosis of insulinoma or pheochromocytoma